4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities.

      1
      Leukemia

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Inhibitor of Apoptosis (IAP) proteins exert essential functions during tumorigenesis as well as treatment resistance by simultaneously blocking cell death pathways and promoting cell survival. As IAP proteins are typically aberrantly expressed in human cancers including hematological malignancies, they represent in principle promising targets for therapeutic interventions. There are currently exciting opportunities to rationally exploit the therapeutic targeting of IAP proteins for the treatment of leukemia and lymphoma. Further insights into the signaling pathways that are under the control of IAP proteins and into the specific IAP protein-dependent vulnerabilities of hematological neoplasms are expected to pave the avenue to novel treatment strategies.

          Related collections

          Author and article information

          Journal
          Leukemia
          Leukemia
          1476-5551
          0887-6924
          Jul 2014
          : 28
          : 7
          Affiliations
          [1 ] Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Frankfurt, Germany.
          Article
          leu201456
          10.1038/leu.2014.56
          24487414
          456bdf6f-ae4f-45d3-a184-dfc5c8ac47a9
          History

          Comments

          Comment on this article